Effects of Sickle Cell Trait and Hemoglobin C Trait on Determinations of HbA1c by an Immunoassay Method

Roberts, William L.; McCraw, Mary; Cook, Curtiss B.

doi:10.2337/diacare.21.6.983

Cited by 33 publications

(15 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Relatos de diferentes interferências, em diferentes métodos, têm sido publicados nos últimos anos (69)(70)(71)(72)(73)(74), enfatizando que cada laboratório deve ter conhecimento da influência das hemoglobinopatias no método que está sendo empregado. A interferência das hemoglobinas anômalas é maior nos métodos com base na separação de cargas, como HPLC de troca catiônica.…”

Section: Fatores Que Afetam Os Resultadosunclassified

Glico-hemoglobina (HbA1c): aspectos clínicos e analíticos

Camargo

Gross

2004

Arq Bras Endocrinol Metab

View full text Add to dashboard Cite

RESUMOA glico-hemoglobina (GHb) é um parâmetro importante no controle glicêmico de pacientes com DM. Vários estudos clínicos mostraram claramente que a melhora no controle glicêmico está fortemente associada com a diminuição no desenvolvimento e/ou progressão das complicações em diabetes melito tipos 1 e 2. A medida exata e precisa da GHb é uma questão importante para os laboratórios clínicos. Vários fatores afetam os resultados e podem levar a resultados errôneos. Nesta revisão, discutimos os problemas da padronização da determinação da GHb para monitorar a terapia diabética e também os principais fatores interferentes. Os métodos para GHb podem ser diferentemente afetados pelas interferências. O efeito da interferência pode ser clinicamente mais relevante com o pior controle glicêmico. O laboratório deve estar atento para estes fatores para evitar confusão na interpretação clínica dos resultados, e os clínicos devem contatar o laboratório sempre que houver discrepância entre a impressão clínica e o resultado laboratorial. Glycohemoglobin (GHb) has a key role in the assessment of glycemic control in diabetic patients. Several studies have clearly shown that improved glycemic control is strongly associated with decreased development and/or progression of diabetic complications in both type 1 and 2 diabetes mellitus. Therefore, accurate determination of GHb concentration is an important issue for clinical laboratories. Several factors may affect and lead to erroneous results. We discuss the problems of standardization of GHb measurements for monitoring glycemic control and also consider the potential interfering factors on GHb measurements. Moreover, GHb assays may be affected by interference in different ways. The effect of interference may be more clinically relevant with poor metabolic control. Laboratory staff must be aware of all pitfalls to avoid adding more confusion to the clinical interpretation of HbA 1c values and physicians should contact laboratories if discrepancies between clinical impressions and laboratory data are observed.

show abstract

Section: Fatores Que Afetam Os Resultadosunclassified

Glico-hemoglobina (HbA1c): aspectos clínicos e analíticos

Camargo

Gross

2004

Arq Bras Endocrinol Metab

View full text Add to dashboard Cite

show abstract

“…Hemoglobin S trait interferes with some assay methods (53)(54)(55), but only 14% of labs currently use methods with clinically significant hemoglobin S interference, and this is expected to come down to 5% by mid-2008 with the modification of a widely used method. About 11% of laboratories currently have interference from hemoglobin C, but this will also drop to about 5% by mid-2008.…”

Section: How Would Confounders and Effect Modifiers Of Hba1c Affect Rmentioning

confidence: 98%

A New Look at Screening and Diagnosing Diabetes Mellitus

Saudek

Herman

Sacks

et al. 2008

The Journal of Clinical Endocrinology &Amp; Metabolism

371

281

View full text Add to dashboard Cite

The main factors in support of using HbA1c as a screening and diagnostic test include: 1) HbA1c does not require patients to be fasting; 2) HbA1c reflects longer-term glycemia than does plasma glucose; 3) HbA1c laboratory methods are now well standardized and reliable; and 4) errors caused by nonglycemic factors affecting HbA1c such as hemoglobinopathies are infrequent and can be minimized by confirming the diagnosis of diabetes with a plasma glucose (PG)-specific test. Specific recommendations include: 1) screening standards should be established that prompt further testing and closer follow-up, including fasting PG of 100 mg/dl or greater, random PG of 130 mg/dl or greater, or HbA1c greater than 6.0%; 2) HbA1c of 6.5-6.9% or greater, confirmed by a PG-specific test (fasting plasma glucose or oral glucose tolerance test), should establish the diagnosis of diabetes; and 3) HbA1c of 7% or greater, confirmed by another HbA1c- or a PG-specific test (fasting plasma glucose or oral glucose tolerance test) should establish the diagnosis of diabetes. The recommendations are offered for consideration of the clinical community and interested associations and societies.

show abstract

“…FBG was tested after 12 h fasting on day 28 by using a blood glucose meter (Bayer, Leverkusen, Germany). FINS levels and HbA1c were measured by immunoassay method . The index of homeostasis model assessment of insulin resistance (HOMA‐IR) was calculated as follows: FBG (mmol L −1 ) × FINS (mIU L −1 ) / 22.5 …”

Section: Methodsmentioning

confidence: 99%